These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 7774513)

  • 21. Prevention of deep-vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: a pharmacoeconomic evaluation.
    Menzin J; Richner R; Huse D; Colditz GA; Oster G
    Ann Pharmacother; 1994 Feb; 28(2):271-5. PubMed ID: 8173149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of enoxaparin in prevention of deep venous thrombosis in hip and knee surgery--a comparison with the dihydroergotamine-heparin combination.
    Perhoniemi V; Vuorinen J; Myllynen P; Kivioja A; Lindevall K
    Ann Chir Gynaecol; 1996; 85(4):359-63. PubMed ID: 9014067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease.
    Dunn CJ; Jarvis B
    Drugs; 2000 Jul; 60(1):203-37. PubMed ID: 10929935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of two low-molecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery. Reviparin Study Group.
    Planès A; Vochelle N; Fagola M; Bellaud M
    Blood Coagul Fibrinolysis; 1998 Sep; 9(6):499-505. PubMed ID: 9819000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement.
    O'Brien BJ; Anderson DR; Goeree R
    CMAJ; 1994 Apr; 150(7):1083-90. PubMed ID: 8137188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge.
    Colwell CW; Collis DK; Paulson R; McCutchen JW; Bigler GT; Lutz S; Hardwick ME
    J Bone Joint Surg Am; 1999 Jul; 81(7):932-40. PubMed ID: 10428124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group.
    Bergmann JF; Neuhart E
    Thromb Haemost; 1996 Oct; 76(4):529-34. PubMed ID: 8902991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group.
    Br J Surg; 1997 Aug; 84(8):1099-103. PubMed ID: 9278651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of thromboembolic disease in general surgery with enoxaparin (Clexane).
    Samama M; Combe S
    Acta Chir Scand Suppl; 1990; 556():91-5. PubMed ID: 1963022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery.
    De A; Roy P; Garg VK; Pandey NK
    Blood Coagul Fibrinolysis; 2010 Jan; 21(1):57-61. PubMed ID: 19844176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group.
    Colwell CW; Spiro TE; Trowbridge AA; Stephens JW; Gardiner GA; Ritter MA
    Clin Orthop Relat Res; 1995 Dec; (321):19-27. PubMed ID: 7497668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement.
    Eriksson BI; Wille-Jørgensen P; Kälebo P; Mouret P; Rosencher N; Bösch P; Baur M; Ekman S; Bach D; Lindbratt S; Close P
    N Engl J Med; 1997 Nov; 337(19):1329-35. PubMed ID: 9358126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review of enoxaparin and its clinical applications in venous and arterial thromboembolism.
    Turpie AG; Mason JA
    Expert Opin Pharmacother; 2002 May; 3(5):575-98. PubMed ID: 11996636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis.
    Gonzalez-Fajardo JA; Arreba E; Castrodeza J; Perez JL; Fernandez L; Agundez I; Mateo AM; Carrera S; Gutiérrez V; Vaquero C
    J Vasc Surg; 1999 Aug; 30(2):283-92. PubMed ID: 10436448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease.
    Kleber FX; Witt C; Vogel G; Koppenhagen K; Schomaker U; Flosbach CW;
    Am Heart J; 2003 Apr; 145(4):614-21. PubMed ID: 12679756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin.
    Fitzgerald RH; Spiro TE; Trowbridge AA; Gardiner GA; Whitsett TL; O'Connell MB; Ohar JA; Young TR;
    J Bone Joint Surg Am; 2001 Jun; 83(6):900-6. PubMed ID: 11407799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent advances in the use of low molecular weight heparins as prophylaxis for deep vein thrombosis.
    Colwell CW
    Orthopedics; 1994 Jul; 17 Suppl():5-7. PubMed ID: 7937386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enoxaparin in the prevention of deep venous thrombosis.
    Ament PW; Bertolino JG
    Am Fam Physician; 1994 Dec; 50(8):1763-8. PubMed ID: 7977005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors.
    Dickinson LD; Miller LD; Patel CP; Gupta SK
    Neurosurgery; 1998 Nov; 43(5):1074-81. PubMed ID: 9802851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.
    Dunn CJ; Sorkin EM
    Drugs; 1996 Aug; 52(2):276-305. PubMed ID: 8841743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.